This filing contains only routine governance changes with no financial data or strategic updates. No trading action warranted. Monitor upcoming quarterly results for fundamental performance signals.
RDY drugs
RDY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $12.46entry
- T+1 · 6mo ago +4.25%α +3.68% · $12.99
- T+5 · 6mo ago +9.15%α +9.07% · $13.60
- T+20 · 5mo ago +6.74%α +8.47% · $13.30
- T+60 · 3mo ago −2.81%α −7.19% · $12.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's filed a routine 6-K reporting board meeting outcomes: re-appointment of an independent director, appointment of a new independent director, appointment of Deloitte as statutory auditor, re-appointment of cost auditor, and elevation of a senior management personnel. No financial results, guidance, or material business developments were disclosed.
Key Facts
- Board re-appointed Dr. K P Krishnan as Independent Director for a second term from Jan 7, 2027 to Jan 6, 2032
- Board appointed Mr. Srikanth Velamakanni as Independent Director for a term from Jul 1, 2026 to Jun 30, 2031
- Board appointed Deloitte Haskins & Sells LLP as statutory auditors for five years from the 42nd AGM
- Board re-appointed M/s Sagar & Associates as cost auditors for FY 2026-27
- Mr. Sandeep Khandelwal elevated to Senior Management Personnel and Management Council member
- No financial results, guidance, or material business updates were provided
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- No material risks identified from this routine filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000293 |
| Document: 0001575872-26-000293-index.html | 0001575872-26-000293 |
| Document: 0001575872-26-000293.txt | 0001575872-26-000293 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers